{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-126211","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.273384+00:00","generated_at":"2026-05-15T08:49:01.319961+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CV Sciences FY2025 revenue down 12% to $13.8M; adjusted EBITDA loss narrows to $0.3M","bullets":["Revenue $13.8M for FY2025 vs $15.7M in 2024, a 12.2% decline on lower volume and regulatory headwinds.","Gross margin improved to 49.0% from 45.6%; operating loss reduced to $0.5M from $2.2M.","Adjusted EBITDA loss was $0.3M, improved from $0.8M in 2024; Q4 2025 delivered positive adjusted EBITDA of $0.1M.","Cash balance $0.3M at year-end; completed debt restructuring in Q1 2026 to strengthen financial position.","Launched 39 new products since Jan 2023; new products contributed 39% of FY2025 net revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-126211","json":"https://secwatch.observer/filing/0001193125-26-126211.json","markdown":"https://secwatch.observer/filing/0001193125-26-126211.md","text":"https://secwatch.observer/filing/0001193125-26-126211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000119312526126211/0001193125-26-126211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000119312526126211/cvsi-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:49:01.319961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52dfa275f838b3ba9243092e98c54e2bbb9802da","claim":"CV Sciences, Inc. reported the year and quarter ended December 31, 2025 results: revenue $13.8 million.","evidence_excerpt":"its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights • Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for the fourth quarter 2024 and $3.3 million for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1510964/000119312526126211/0001193125-26-126211-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year and quarter ended December 31, 2025"},{"label":"Revenue","value":"$13.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}